Targeting Histone Acetyltransferase MOZ/KAT6A as a New Avenue for Hematological Tumor Therapy-Reference-Cited by-同舟云学术

Targeting Histone Acetyltransferase MOZ/KAT6A as a New Avenue for Hematological Tumor Therapy

Published:2020-03-27 Issue:5 Volume:20 Page:333-335
ISSN:1568-0266
Container-title:Current Topics in Medicinal Chemistry
language:en
Short-container-title:CTMC

Author:

Zhou Chongchen¹,Zhu Hai-liang¹,Duan Yongtao¹

Affiliation:

1. Henan Provincial Key Laboratory of Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, 450018, China

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,General Medicine

Reference10 articles.

1. Duan Y-T.; Sangani C.B.; Liu W.; Soni K.V.; Yao Y.; New promises to cure cancer and other genetic diseases/disorders: Epi-drugs through epigenetics. Curr Top Med Chem 2019,19(12),972-994

2. Liu W.; Wang X.; Zhu H.; Duan Y.; Precision tumor medicine and drug targets. Curr Top Med Chem 2019,19(17),1488-1489

3. Huang F.; Abmayr S.M.; Workman J.L.; Regulation of KAT6 acetyltransferases and their roles in cell cycle progression, stem cell maintenance, and human disease. Mol Cell Biol 2016,36(14),1900-1907

4. Leaver D.J.; Cleary B.; Nguyen N.; Priebbenow D.L.; Lagiakos H.R.; Sanchez J.; Xue L.; Huang F.; Sun Y.; Mujumdar P.; Discovery of benzoylsulfonohydrazides as potent inhibitors of the histone acetyltransferase KAT6A. J Med Chem 2019,62(15),7146-7159

5. Baell J.B.; Leaver D.J.; Hermans S.J.; Kelly G.L.; Brennan M.S.; Downer N.L.; Nguyen N.; Wichmann J.; McRae H.M.; Yang Y.; Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth. Nature 2018,560(7717),253-257

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of MOZ/KAT6A in hematological malignancies and advances in MOZ/KAT6A inhibitors;Pharmacological Research;2021-12

2. Indazole as a Privileged Scaffold: The Derivatives and their Therapeutic Applications;Anti-Cancer Agents in Medicinal Chemistry;2021-05

3. MOZ/KAT6A: a promising target for acute myeloid leukemia therapy;Future Medicinal Chemistry;2020-05